title: Bioequivalence of racemic drugs.
abstract: Although pharmacokinetic and pharmacodynamic differences between the enantiomers of a chiral drug have been known or suspected for many years, racemate drugs have frequently been developed and approved without clinical pharmacologic consideration of their chiral components. In the late 1970s, the technology to isolate, manufacture, and detect pure enantiomers of racemate drugs became generally available. This availability has created new demands on both pharmaceutical firms and regulatory agencies. To prepare for this new technology, the Center for Drug Evaluation and Research at the Food and Drug Administration is formulating a policy statement to guide evaluation of new chiral drugs. At this time, it appears that whatever new policies are developed will not necessarily be applied retroactively to previously approved racemate drugs. Additional policies to guide the development and approval of generic and OTC chiral drugs may be required. In the Office of Generic Drugs in the Center, abbreviated new drug or antibiotic applications are approved on the basis of adequate chemistry, manufacturing, and control procedures and comparative pharmacokinetics (bioequivalence). The generic drug must be a racemate or single enantiomer if the corresponding innovator drug is a racemate or single enantiomer respectively. Whether a generic firm will be required to provide bioequivalence information on enantiomers of a racemate is determined on a case-by-case basis. Although it might be claimed that a generic drug product should be required only to undergo the same general kind of pharmaceutical evaluation as did the innovator, there may be instances when the approval of a generic drug or antibiotic will require measurement of specific enantiomers of a chiral drug.
authors.affiliation: Office of Generic Drugs, Food and Drug Administration, Rockville, Maryland.
authors.forename: S G
authors.initials: SG
authors.lastname: Nerurkar
authors.forename: S V
authors.initials: SV
authors.lastname: Dighe
authors.forename: R L
authors.initials: RL
authors.lastname: Williams
mesh_terms: D017277:Drug Approval; D010599:Pharmacokinetics; D010601:Pharmacology, Clinical; D011050:Policy Making; D013237:Stereoisomerism; D013810:Therapeutic Equivalency